Recently Immunovaccine, Inc. announced the launch of its DPX-NEO program to foster and expand its DepoVax-based vaccines for use in immuno-oncology clinical settings.
The program was initiated to develop neoepitopes – molecules that are usually the target of an immune response, but in this case are specifically produced by tumor cells. As a result, they are tumor specific and believed to show great promise in the field of immunotherapy, since scientists can design vaccines specifically targeting these tumor-neoepitopes.
In this Oncology Associates video, learn more about how immunotherapy cancer treatment works and what types of side effects it may cause with oncologist Stephen Lemon MD.
Read full article here: http://bit.ly/1WkhaI7
Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
